What are the American College of Obstetricians and Gynecologists (ACOG) guidelines for managing a short cervical length in pregnancy, including recommendations for cervical cerclage, progesterone therapy, and alternative interventions?

ACOG/SMFM Guidelines on Short Cervix and Cervical Cerclage

For singleton pregnancies without prior spontaneous preterm birth and a short cervix, vaginal progesterone is the primary intervention—cerclage is NOT recommended unless there is cervical dilation. 1

Diagnosis of Short Cervix

All cervical length measurements must be performed via transvaginal ultrasound using standardized techniques (Perinatal Quality Foundation or Fetal Medicine Foundation protocols). 1

• Short cervix is defined as ≤25 mm in the midtrimester for patients without prior spontaneous preterm birth 1
• Assessment should occur at the 18-22 week anatomy scan
• Transvaginal approach is mandatory for therapeutic decision-making (transabdominal screening alone is insufficient) 1

Management Algorithm for Singleton Pregnancies WITHOUT Prior Preterm Birth

Cervical Length ≤20 mm (diagnosed before 24 weeks)

Prescribe vaginal progesterone (GRADE 1A recommendation) 1

• This is the strongest evidence-based intervention
• Reduces preterm birth risk significantly

Cervical Length 21-25 mm

Consider vaginal progesterone based on shared decision-making (GRADE 1B) 1

• Discuss risks/benefits with patient
• Weaker evidence but reasonable option

Cervical Length 10-25 mm (no dilation)

Do NOT place cerclage (GRADE 1B) 1

• This is a critical point: cerclage is contraindicated in this population without cervical dilation
• Even with extremely short cervix, progesterone alone is recommended unless dilation is present

What NOT to Do

Avoid these interventions (all GRADE 1B recommendations against): 1

• 17-alpha hydroxyprogesterone caproate (17-OHP) - including compounded formulations - should NOT be prescribed for short cervix 1
• Cervical pessary - no benefit demonstrated for singleton pregnancies with short cervix 1
• Cerclage without cervical dilation - specifically contraindicated in patients without prior preterm birth history 1

Twin Gestations

Do NOT routinely use progesterone, pessary, or cerclage for cervical shortening in twins outside clinical trials (GRADE 1B) 1

• None of these interventions have proven benefit in twin pregnancies
• Should only be considered in research settings

Key Clinical Pitfalls

1. Don't confuse populations: These guidelines specifically address patients WITHOUT prior spontaneous preterm birth. Different recommendations apply to those with prior preterm birth history.

2. Measurement technique matters: Only transvaginal measurements should guide treatment decisions. Transabdominal findings require transvaginal confirmation. 1

3. Timing is critical: Interventions are only recommended when short cervix is diagnosed before 24 weeks gestation. 1

4. Dilation changes everything: The presence of cervical dilation (≥1 cm) in the context of short cervix may warrant different management, potentially including physical exam-indicated cerclage, but this represents a different clinical scenario than asymptomatic short cervix alone.

Rationale Behind Recommendations

The evidence strongly supports vaginal progesterone over cerclage in this population because:

• Multiple high-quality trials demonstrate progesterone reduces preterm birth in singleton pregnancies with short cervix
• Cerclage trials in patients without prior preterm birth have not shown benefit and may cause harm
• The mechanism of cervical shortening differs between those with and without prior preterm birth history

These 2024 SMFM guidelines represent the most current evidence-based approach and supersede older recommendations that were more liberal with cerclage indications. 1